Investor Newsletter

Issue 04 2023

MicroPort®



MicroPort® Announces Release of TARGET-FIRST Study Design for the Firehawk Coronary Stent

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) recently announced the online publication on the Euro Intervention journal of the design of the Target-First study. This European study aims to determine whether short dual antiplatelet therapy (DAPT) is non-inferior to standard DAPT for patients with acute myocardial infarction (AMI) who have underwent complete revascularization with Firehawk, an abluminal in-groove biodegradable polymer rapamycin eluting stent.

The article, whose first author is Prof. Giuseppe Tarantini from University Hospital of Padova, Italy, states: “Based on the latest knowledge and technological advancements, it is still debatable whether a modern revascularization approach in the setting of AMI, including complete revascularization with newer-generation, highly biocompatible drug-eluting stents, requires prolonged dual antiplatelet therapy (DAPT).”

MicroPort

Endovastec™ Received Approval for Hercules™ -LP Thoracic Stent Graft in Singapore

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has recently received registration approval from the Health Sciences Authority (HSA) of Singapore for its HerculesTM Thoracic Stent Graft with Low Profile Delivery System covered stent (hereafter referred to as "Hercules TM -LP Stent Graft"). This is the first product of MicroPort Endovastec to have been approved for market in Singapore.

The Hercules TM -LP Stent Graft received CE certification from the EU in 2020 and has now entered clinical use in 16 overseas countries worldwide, and is successfully treating thousands of patients with aortic diseases. In recent years, the demand for medical devices in Singapore has grown rapidly. The approval of the Hercules TM -LP Stent Graft registration in Singapore will lay the foundation for the company to further expand into the Southeast Asian market and open new possibilities. MicroPort Endovastec will continue to promote its high-quality innovative products to more countries around the world in order to benefit more patients.



MicroPort

Endovastec™ has Completed the First Clinical Cases of Two Products in Colombia

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has recently completed their first successful cases of its HerculesTM Thoracic Stent Graft with Low Profile Delivery System (hereinafter referred to as "HerculesTM -LP Stent Graft") and MinosTM Abdominal Aortic Stent Graft and Delivery System (hereafter referred to as “MinosTM Stent Graft System”) in Colombia, marking the official entry of Endovastec™'s products into the Colombian market.

Professor Samira Ali Cure expressed her appreciation of both the HerculesTM -LP Stent Graft and MinosTM Stent Graft System once again after the surgery. She explained, "The ingenious design concept and low delivery system outer diameter of the two products ensures the stent system not only has accurate positioning and precise deployment, but also improves the compatibility of the stent to the anatomy, meeting the requirements of more complex vascular access arteries such as twisting and narrowing.
At the same time, the delivery system’s e
asy-to-operate, low learning curve reduces
surgery time and improves the
safety of surgery."

MicroPort

MicroPort EP Successfully Performed the First 3D Surgeries in Egypt with its Columbus™ 3D EP Navigation System

Shanghai MicroPort EP MedTech Co., Ltd. (referred to as "MicroPort EP") has recently performed its first series of successful 3D surgeries in the Egyptian market. The surgeries were performed by the electrophysiology experts of Dr. Ahmet's team at the Welcare Hospital in Cairo, Egypt, using MicroPort EP's Columbus™ 3D EP Navigation System ("Columbus™") and its accompanying products, including the FireMagic™ 3D Irrigated Ablation Catheter, the EasyFinder™ Steerable Curve Diagnostic Catheter, and the PathBuilder™ Transseptal Guiding Introducer and needle. These surgeries included one atrial flutter ablation, two atrioventricular nodal reentrant tachycardia ablations, and one atrial fibrillation treatment.

The surgeries mentioned fully demonstrated the functions of real-time, precise navigation, as well as the efficient modeling of the Columbus™ system. After the surgery, Dr. Ahmet, an electrophysiology expert, stated that the Columbus™ system has clear and stable signals, is easy to operate, and the catheter bending is precise and simple to control. He looks forward to the future application of various EP catheters in a wide range of complex cases.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com